Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

BBIO

BridgeBio Pharma Inc

Apr 18 • 04:00PM ET

24.95

Dollar change -0.03
Percentage change -0.12	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK VBR IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.95	Insider Own	24.74%	Shs Outstand	175.08M	Perf Week	-12.02%
Market Cap	4.60B	Forward P/E	-	EPS next Y	-2.99	Insider Trans	-0.41%	Shs Float	138.81M	Perf Month	-12.24%
Income	-643.20M	PEG	-	EPS next Q	-0.92	Inst Own	71.52%	Short Float	10.29%	Perf Quarter	-33.57%
Sales	9.30M	P/S	494.84	EPS this Y	20.57%	Inst Trans	2.45%	Short Ratio	8.20	Perf Half Y	-6.83%
Book/sh	-7.73	P/B	-	EPS next Y	4.81%	ROA	-110.00%	Short Interest	14.28M	Perf Year	64.69%
Cash/sh	2.45	P/C	10.19	EPS next 5Y	-	ROE	-	52W Range	12.75 - 44.32	Perf YTD	-38.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.29%	ROI	-168.62%	52W High	-43.70%	Beta	1.08
Dividend TTM	-	Quick Ratio	3.32	Sales past 5Y	117.77%	Gross Margin	20.03%	52W Low	95.69%	ATR (14)	1.31
Dividend Ex-Date	-	Current Ratio	3.32	EPS Y/Y TTM	-21.03%	Oper. Margin	-6443.56%	RSI (14)	30.56	Volatility	3.98% 4.10%
Employees	550	Debt/Eq	-	Sales Y/Y TTM	-88.02%	Profit Margin	-6913.92%	Recom	1.38	Target Price	49.25
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-4.61%	Payout	-	Rel Volume	1.14	Prev Close	24.98
Sales Surprise	-61.63%	EPS Surprise	-10.48%	Sales Q/Q	-6.68%	Earnings	Feb 22 BMO	Avg Volume	1.74M	Price	24.95
SMA20	-12.08%	SMA50	-19.18%	SMA200	-18.38%	Trades		Volume	1,984,108	Change	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	SVB Leerink	Outperform	$66 → $24
Dec-27-21	Reiterated	Mizuho	Buy	$86 → $25
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy	$75
May-21-21	Initiated	UBS	Buy	$80
Mar-22-21	Reiterated	Goldman	Buy	$83 → $91
Feb-22-21	Resumed	JP Morgan	Overweight	$78
Feb-09-21	Resumed	Goldman	Buy	$83
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$64 → $87
Dec-10-20	Reiterated	H.C. Wainwright	Buy	$53 → $64
Jun-25-20	Initiated	BofA/Merrill	Neutral	$38
May-19-20	Initiated	BTIG Research	Buy	$49

Show Previous Ratings

Apr-10-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-07-24 01:15PM	BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Mar-27-24 09:25AM	TipRanks Perfect 10 List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal (TipRanks)
Mar-20-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-24 11:53PM	BridgeBio Pharma Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -8.51%
04:17PM	Loading…
Mar-04-24 04:17PM	BridgeBio Pharma Announces Proposed Public Offering of Common Stock (GlobeNewswire) -9.19%
04:05PM	BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug (Investor's Business Daily)
03:00AM	Bayer pays $310M to buy into BridgeBio heart drug (BioPharma Dive)
02:30AM	BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe (Reuters)
02:30AM	BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? (Investor's Business Daily)
02:30AM	BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM (GlobeNewswire)
Feb-22-24 08:40AM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:53AM	BridgeBio Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:52AM	BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials (GuruFocus.com)
07:30AM	BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update (GlobeNewswire)
10:00AM	Loading…
Feb-15-24 10:00AM	Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for (Zacks) +14.14%
06:54AM	Alnylam changes to heart drug trial spark doubts, sinking shares (BioPharma Dive)
Feb-07-24 07:34AM	BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan (GlobeNewswire)
07:22AM	BridgeBio sells partial rights to dwarfism drug for $100M (BioPharma Dive)
Feb-06-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-24 07:30AM	BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Feb-02-24 07:00AM	BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months (GlobeNewswire)
Jan-30-24 07:00AM	Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics (PR Newswire)
Jan-29-24 12:35PM	3 Groundbreaking Biotech Stocks to Invest in Now (InvestorPlace) +5.29%
Jan-18-24 07:59PM	BridgeBio Pharma Inc Director Hannah Valantine Sells 2,915 Shares (GuruFocus.com)
07:00AM	BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines (GlobeNewswire)
06:21AM	BridgeBio strikes drug royalty deal for cash infusion (BioPharma Dive)
Jan-12-24 09:23AM	16 Best Mid-Cap Growth Stocks To Buy Now (Insider Monkey)
Jan-10-24 05:15PM	BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine (GlobeNewswire)
07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Loading…
Jan-03-24 04:30PM	BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference (GlobeNewswire) -6.43%
07:30AM	BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON) (GlobeNewswire)
06:45AM	2 Biotechs That Could Get Bought Out in 2024 (Motley Fool)
Dec-28-23 12:20PM	With BridgeBio Pharma's DNA, the Stock Could Continue to Soar Higher (TheStreet.com)
Dec-26-23 06:56PM	13 High Growth Healthcare Stocks to Buy (Insider Monkey)
Dec-18-23 05:34AM	3 Russell 2000 Stocks That Are About to Get Absolutely Crushed (InvestorPlace)
Dec-13-23 07:30AM	BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia (GlobeNewswire) +5.14%
Dec-08-23 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
07:44AM	BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Nov-21-23 05:03PM	Insider Sell Alert: BridgeBio Pharma Inc's Brian Stephenson Unloads 22,685 Shares (GuruFocus.com)
Nov-12-23 10:30AM	BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Nov-09-23 07:30AM	BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023 (GlobeNewswire) -7.89%
Nov-08-23 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-02-23 09:21AM	BridgeBio Pharma Inc (BBIO) Reports Q3 2023 Financial Results (GuruFocus.com)
07:45AM	BridgeBio Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-26-23 10:02AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-24-23 07:57PM	Why BridgeBio Pharma Was a Healthy Stock Today (Motley Fool)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-11-23 07:30AM	BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-10-23 07:30AM	BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1) (GlobeNewswire)
Oct-09-23 07:30AM	BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan ( DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) (GlobeNewswire)
Oct-03-23 07:31AM	BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments (Business Wire)
Sep-25-23 07:30AM	BridgeBio Pharma Announces $250 Million Private Placement Equity Financing (GlobeNewswire)
Sep-13-23 08:08AM	Buy List Alert: 3 Pharma Stocks with Positive Trial Updates (InvestorPlace)
Sep-08-23 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 07:30AM	BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-06-23 07:30AM	BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia (GlobeNewswire)
Aug-28-23 04:06PM	Why BridgeBio's Battle With Pfizer In Heart Disease Treatment Is Just Heating Up (Investor's Business Daily)
10:00AM	Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better. (Investor's Business Daily)
Aug-27-23 06:15AM	BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023 (GlobeNewswire)
Aug-24-23 04:01PM	BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-16-23 06:35AM	15 Best Performing Stocks in the Last 6 Months (Insider Monkey)
Aug-14-23 06:01PM	Andreas Halvorsen's Q2 2023 13F Filing Update (GuruFocus.com)
Aug-09-23 10:07AM	Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It? (Motley Fool)
Aug-04-23 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:28AM	12 Best Biotech ETFs To Buy (Insider Monkey)
Aug-03-23 09:05AM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:57AM	BridgeBio Pharma: Q2 Earnings Snapshot (AP Finance)
07:30AM	BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Jul-31-23 07:30AM	BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study (GlobeNewswire)
06:13AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Jul-21-23 10:44AM	Why Shares of BridgeBio Pharma Skyrocketed This Week (Motley Fool)
10:11AM	Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues (Zacks)
Jul-18-23 11:25AM	BridgeBio Pharma Surges on Positive Heart Drug News (GuruFocus.com)
09:53AM	BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study (Zacks)
09:16AM	Company News for Jul 18, 2023 (Zacks)
07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-23 08:40PM	BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last? (Zacks) +75.85%
04:07PM	BridgeBio Launches 76% And Pulls Its Rival Higher On Bullish Heart Drug News (Investor's Business Daily)
02:21PM	Stocks to Watch Monday: Activision, Ford, Tesla, AT&T (The Wall Street Journal)
12:29PM	BridgeBio Launches 80% And Pulls Its Rivals Higher On Bullish Heart Drug News (Investor's Business Daily)
12:25PM	BridgeBio, Sony rise; Rivian, Ford fall, Monday, 7/17/2023 (AP Finance)
11:55AM	I'm Chase Trading This Biotech Stock Because I Like Its Odds (TheStreet.com)
10:37AM	AT&T downgrade, BridgeBio Pharma's heart treatment, PepsiCo shares slip: Trending stocks (Yahoo Finance Video)
10:13AM	BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease (Investor's Business Daily)
10:01AM	BridgeBio Surges After Heart Drug Succeeds in Pivotal Trial (Bloomberg)
09:09AM	You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers (Motley Fool)
07:23AM	UPDATE 1-BridgeBio Pharma's heart disease drug meets main goal in late-stage study (Reuters)
07:09AM	BridgeBio Pharma says heart disease therapy meets main goal in late-stage study (Reuters)
07:00AM	BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) (GlobeNewswire)
Jul-16-23 08:00PM	2 Nasdaq Stocks That Could Soar This Week (Motley Fool)
Jul-14-23 04:01PM	BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023 (GlobeNewswire) +5.26%
Jul-12-23 04:31PM	Burjeel Holdings to Launch Rare Disease Research & Development Project NADER in Partnership with US-based BridgeBio Pharma (GlobeNewswire)
Jun-27-23 05:31AM	2 Growth Stocks With Major Incoming Catalysts (Motley Fool) +5.16%
Jun-20-23 07:30AM	BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference (GlobeNewswire) +10.06%
Jun-15-23 02:04PM	Why BridgeBio Pharma Stock Is Plunging Today (Motley Fool) -8.11%
Jun-13-23 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.95%
Jun-08-23 07:30AM	BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference (GlobeNewswire)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scott Randal W.	Director	Mar 01 '24	Sale	34.00	2,500	85,000	6,500	Mar 05 04:00 PM
Valantine Hannah	Director	Feb 15 '24	Option Exercise	8.45	2,915	24,632	4,679	Feb 20 04:03 PM
Valantine Hannah	Director	Feb 15 '24	Sale	37.75	2,915	110,041	1,764	Feb 20 04:03 PM
Valantine Hannah	Director	Jan 16 '24	Option Exercise	8.45	2,915	24,632	4,679	Jan 18 04:10 PM
Valantine Hannah	Director	Jan 16 '24	Sale	37.97	2,915	110,683	1,764	Jan 18 04:10 PM
MCCORMICK FRANK	Director	Dec 26 '23	Sale	42.06	100,000	4,206,000	627,689	Dec 28 04:00 PM
Scott Randal W.	Director	Dec 18 '23	Sale	40.00	2,000	80,000	9,000	Dec 20 04:00 PM
Valantine Hannah	Director	Dec 15 '23	Option Exercise	8.45	2,915	24,632	4,679	Dec 19 04:00 PM
Valantine Hannah	Director	Dec 15 '23	Sale	36.12	2,915	105,290	1,764	Dec 19 04:00 PM
Scott Randal W.	Director	Dec 01 '23	Sale	29.40	2,500	73,500	11,000	Dec 05 04:00 PM
Kumar Neil	CEO and President	Nov 17 '23	Sale	29.10	51,552	1,500,038	4,813,197	Nov 20 04:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Nov 17 '23	Sale	29.10	22,685	660,059	36,710	Nov 20 04:00 PM
Valantine Hannah	Director	Nov 15 '23	Option Exercise	8.45	2,915	24,632	4,679	Nov 17 04:09 PM
Valantine Hannah	Director	Nov 15 '23	Sale	30.00	2,915	87,450	1,764	Nov 17 04:09 PM
Scott Randal W.	Director	Sep 05 '23	Sale	30.00	2,500	75,000	13,500	Sep 07 04:00 PM
Kumar Neil	CEO and President	Aug 17 '23	Sale	28.59	51,552	1,473,784	4,813,197	Aug 18 04:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Aug 17 '23	Sale	28.59	22,683	648,455	36,710	Aug 18 04:00 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jul 18 '23	Sale	35.00	1,500,000	52,500,000	25,120,991	Jul 19 09:33 PM
Kumar Neil	CEO and President	May 17 '23	Sale	14.01	51,552	722,218	4,813,197	May 18 04:07 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	May 17 '23	Sale	14.01	24,424	342,168	36,408	May 18 04:02 PM
Kumar Neil	CEO and President	May 03 '23	Sale	14.18	120,000	1,701,744	1,012,722	May 05 04:03 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	May 03 '23	Sale	14.18	64,929	920,693	36,408	May 05 04:01 PM

Open in Screener

ALEC

Alector Inc

Apr 18 • 04:00PM ET

5.09

Dollar change +0.02
Percentage change 0.39	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO IBB SCHA VTWO VHT LABU IWC

Index	RUT	P/E	-	EPS (ttm)	-1.56	Insider Own	23.96%	Shs Outstand	84.88M	Perf Week	-18.30%
Market Cap	487.37M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	-0.38%	Shs Float	72.80M	Perf Month	-17.90%
Income	-130.39M	PEG	-	EPS next Q	-0.51	Inst Own	65.53%	Short Float	8.89%	Perf Quarter	-11.79%
Sales	97.06M	P/S	5.02	EPS this Y	-34.79%	Inst Trans	0.70%	Short Ratio	9.13	Perf Half Y	-15.73%
Book/sh	1.58	P/B	3.22	EPS next Y	28.54%	ROA	-18.50%	Short Interest	6.47M	Perf Year	-21.99%
Cash/sh	5.73	P/C	0.89	EPS next 5Y	-10.70%	ROE	-74.81%	52W Range	3.66 - 9.06	Perf YTD	-36.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.76%	ROI	-79.21%	52W High	-43.85%	Beta	0.82
Dividend TTM	-	Quick Ratio	3.18	Sales past 5Y	158.96%	Gross Margin	90.88%	52W Low	39.07%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	3.18	EPS Y/Y TTM	3.67%	Oper. Margin	-156.33%	RSI (14)	33.63	Volatility	6.16% 4.91%
Employees	244	Debt/Eq	0.29	Sales Y/Y TTM	-27.36%	Profit Margin	-134.34%	Recom	1.90	Target Price	14.43
Option/Short	Yes / Yes	LT Debt/Eq	0.23	EPS Q/Q	22.49%	Payout	-	Rel Volume	0.58	Prev Close	5.07
Sales Surprise	71.89%	EPS Surprise	36.45%	Sales Q/Q	5.19%	Earnings	Feb 27 AMC	Avg Volume	708.70K	Price	5.09
SMA20	-13.66%	SMA50	-18.35%	SMA200	-18.91%	Trades		Volume	413,026	Change	0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Upgrade	Stifel	Hold → Buy	$8 → $15
Dec-12-23	Initiated	Deutsche Bank	Buy	$12
Sep-25-23	Initiated	Goldman	Sell	$4
Sep-22-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$24 → $12
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $13
Jul-07-22	Initiated	Mizuho	Buy	$15
Apr-13-22	Initiated	Goldman	Sell	$9
Mar-08-22	Downgrade	Stifel	Buy → Hold	$32 → $18
Sep-27-21	Initiated	William Blair	Outperform
Jan-15-21	Resumed	BofA Securities	Buy	$35
Jun-24-20	Initiated	H.C. Wainwright	Buy	$41
Apr-28-20	Initiated	Goldman	Buy	$32
Mar-06-20	Initiated	Citigroup	Buy	$40
Feb-27-20	Initiated	Barclays	Overweight	$36
Feb-19-20	Initiated	Stifel	Buy	$44
Nov-21-19	Initiated	BTIG Research	Buy	$28
Mar-04-19	Initiated	SVB Leerink	Outperform
Mar-04-19	Initiated	Morgan Stanley	Overweight	$27
Mar-04-19	Initiated	BofA/Merrill	Buy	$26

Show Previous Ratings

Feb-28-24 02:02PM	Q4 2023 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
10:13AM	Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-27-24 04:46PM	Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.18%
04:23PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-20-24 04:05PM	Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call (GlobeNewswire)
10:00AM	Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline (Zacks)
Feb-08-24 07:00AM	Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:48AM	Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Feb-07-24 07:00AM	FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire) +5.96%
Jan-25-24 12:00PM	Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-23-24 07:32AM	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs (InvestorPlace)
Jan-19-24 09:20AM	Alector Announces Closing of Public Offering (GlobeNewswire)
Jan-17-24 08:54AM	Alector Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.01%
04:01PM	Loading…
Jan-16-24 04:01PM	Alector Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-08-24 01:25PM	Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 (Investor's Business Daily) +7.34%
Dec-05-23 09:55AM	Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet (Zacks)
Nov-28-23 07:00AM	Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs (GlobeNewswire)
Nov-14-23 09:35AM	Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +14.06%
Nov-08-23 07:00AM	Alector to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.30%
Nov-07-23 06:02PM	Alector: Q3 Earnings Snapshot (Associated Press Finance) +5.12%
05:11PM	Alector Inc (ALEC) Reports Q3 2023 Financial Results with Key Clinical Advancements (GuruFocus.com)
04:05PM	Alector Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire)
Sep-14-23 01:12AM	10% Owner Polaris Venture Management Co. VI, L.L.C. Sells 500,000 Shares of Alector Inc (GuruFocus.com)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
Sep-07-23 07:00AM	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimers Disease (GlobeNewswire) +6.76%
Aug-31-23 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-10-23 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade (Zacks)
05:45PM	Loading…
Aug-03-23 05:45PM	Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:43PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 08:30AM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-13-23 01:29PM	7 Stocks That AI Says Will Make You a Millionaire by 2025 (InvestorPlace)
Jun-06-23 07:00AM	Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Companies Like Alector (NASDAQ:ALEC) Are In A Position To Invest In Growth (Simply Wall St.) -8.20%
May-09-23 09:55AM	Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect? (Zacks)
May-05-23 06:31AM	Benign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share Price (Simply Wall St.) +10.27%
May-04-23 07:35PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:27PM	Alector: Q1 Earnings Snapshot (AP Finance)
04:05PM	Alector Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 07:00AM	Alector to Participate in the BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-01-23 10:01AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-27-23 10:03AM	Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-13-23 12:59PM	Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested three years ago (Simply Wall St.)
08:30AM	Are Options Traders Betting on a Big Move in Alector (ALEC) Stock? (Zacks)
Mar-01-23 04:05PM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-28-23 04:05PM	Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-20-23 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-17-23 06:01AM	Alector, Inc. (NASDAQ:ALEC) is a favorite amongst institutional investors who own 64% (Simply Wall St.)
Feb-16-23 10:01AM	Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Dec-21-22 05:01AM	We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate (Simply Wall St.)
Dec-08-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-22 11:05AM	Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Nov-10-22 05:13AM	Alector Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +19.62%
Nov-08-22 07:45PM	Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Alector Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Nov-04-22 11:05AM	Alector (NASDAQ:ALEC) investors are sitting on a loss of 65% if they invested a year ago (Simply Wall St.)
Nov-03-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-13-22 08:00AM	Alector Announces Promotion of Clare Hunt to Chief People Officer (GlobeNewswire)
Oct-06-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-22 07:00AM	Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimers Disease (AD) (GlobeNewswire) +5.66%
Sep-07-22 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) +8.28%
Aug-09-22 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to Trade (Zacks)
Aug-06-22 08:33AM	Alector, Inc.'s (NASDAQ:ALEC) Stock Is Going Strong: Have Financials A Role To Play? (Simply Wall St.)
Aug-04-22 07:15PM	Alector (ALEC) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:05PM	Alector Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-08-22 10:54AM	AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector (Benzinga)
Jul-07-22 05:59PM	Alzheimer's drug cut loose from Peninsula biotech's collaboration but another survives (American City Business Journals)
Jun-08-22 07:00AM	Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
May-28-22 08:20AM	Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested a year ago (Simply Wall St.)
May-27-22 04:30PM	Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules (GlobeNewswire)
May-05-22 06:25PM	Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.67%
04:05PM	Alector Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-04-22 07:00AM	Alector to Participate at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
May-02-22 07:47AM	New Strong Sell Stocks for May 2nd (Zacks)
Apr-27-22 03:03PM	Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Mar-29-22 04:05PM	Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Mar-15-22 12:04PM	Alector Highlights Mid-Stage Study Data On Lead Dementia Drug (Benzinga)
08:00AM	Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial (GlobeNewswire)
Mar-09-22 07:00AM	Alector to Present at Upcoming Healthcare Conferences (GlobeNewswire) +12.45%
Mar-08-22 07:00AM	Alector to Present New AL001 Data at AD/PD 2022 (GlobeNewswire) -9.70%
Mar-01-22 04:30PM	Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules (GlobeNewswire)
04:05PM	Alector to Participate at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-24-22 06:50PM	Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Alector Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-17-22 03:02PM	Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-22 04:30AM	International Petroleum Corporation Announces Results of Share Repurchase Program (GlobeNewswire)
Feb-07-22 08:30AM	Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer (GlobeNewswire)
Feb-01-22 11:13AM	Alector (ALEC) Surges 8%: Is This an Indication of Further Gains? (Zacks)
Jan-11-22 01:30AM	International Petroleum Corporation to Arrange Fixed Income Investor Meetings (GlobeNewswire) +5.25%
01:30AM	International Petroleum Corporation Announces Corporate Credit Ratings (GlobeNewswire)
Jan-10-22 11:07AM	Why Shehnaaz Suliman threw in with a young biotech for her first CEO gig (American City Business Journals)
Jan-03-22 04:30PM	Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules (GlobeNewswire)
Jan-02-22 06:32AM	Alector, Inc. (NASDAQ:ALEC) Has Found A Path To Profitability (Simply Wall St.)
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-16-21 11:03AM	Peninsula brain drug company snags Genentech vet as president (American City Business Journals)
Dec-15-21 08:30AM	Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development (GlobeNewswire) +7.60%

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenthal Arnon	Chief Executive Officer	Mar 04 '24	Sale	6.92	18,837	130,386	2,000,380	Mar 05 06:00 PM
Kenkare-Mitra Sara	President and Head of R&D	Mar 04 '24	Sale	6.92	10,169	70,387	318,847	Mar 05 06:00 PM
Romano Gary	Chief Medical Officer	Mar 04 '24	Sale	6.92	6,001	41,554	196,313	Mar 05 06:00 PM
GRASSO MARC	Chief Financial Officer	Mar 04 '24	Sale	6.92	5,716	39,562	144,957	Mar 05 06:00 PM
Rosenthal Arnon	Chief Executive Officer	Dec 04 '23	Sale	5.56	23,831	132,500	2,019,217	Dec 06 06:30 PM
Kenkare-Mitra Sara	President and Head of R&D	Dec 04 '23	Sale	5.56	12,519	69,606	329,016	Dec 06 06:30 PM
Romano Gary	Chief Medical Officer	Dec 04 '23	Sale	5.56	5,035	27,995	202,314	Dec 06 06:30 PM
GRASSO MARC	Chief Financial Officer	Dec 04 '23	Sale	5.56	4,574	25,431	150,673	Dec 06 06:30 PM
Polaris Venture Management Co.	10% Owner	Sep 11 '23	Sale	6.00	500,000	3,000,000	10,853,817	Sep 13 04:33 PM
MCGUIRE TERRANCE	Director	Sep 11 '23	Sale	6.00	500,000	3,000,000	10,853,817	Sep 13 04:29 PM
Kenkare-Mitra Sara	President and Head of R&D	Sep 05 '23	Sale	5.19	6,214	32,277	177,935	Sep 06 07:17 PM
Rosenthal Arnon	Chief Executive Officer	Sep 05 '23	Sale	5.19	5,647	29,333	1,645,448	Sep 06 07:18 PM
Romano Gary	Chief Medical Officer	Sep 05 '23	Sale	5.19	2,771	14,393	99,349	Sep 06 07:16 PM
GRASSO MARC	Chief Financial Officer	Sep 05 '23	Sale	5.19	1,114	5,786	32,247	Sep 06 07:14 PM
Rosenthal Arnon	Chief Executive Officer	Jun 02 '23	Sale	6.90	5,255	36,279	1,651,095	Jun 05 06:48 PM
Kenkare-Mitra Sara	President and Head of R&D	Jun 02 '23	Sale	6.90	4,092	28,250	184,149	Jun 05 06:54 PM
Romano Gary	Chief Medical Officer	Jun 02 '23	Sale	6.90	2,617	18,067	102,120	Jun 05 06:50 PM
GRASSO MARC	Chief Financial Officer	Jun 02 '23	Sale	6.90	1,050	7,249	33,361	Jun 05 06:52 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BBIO

BridgeBio Pharma Inc

ALEC

Alector Inc

Upgrade your FINVIZ experience